Zkusit zdarma
InflaRx N.V.

InflaRx N.V.

IFRX
Cena:
$ 2.61
+0.14 (5.67%)
Valuace
70
Růst
30
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

21:51 08-05-2026

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal D...

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

16:04 08-05-2026

InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the ...

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

8:15 08-05-2026

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a...

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

8:30 06-05-2026

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a b...

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

8:25 06-05-2026

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c...

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

7:30 04-05-2026

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical com...

InflaRx to Report First Quarter 2026 Results on May 7, 2026

InflaRx to Report First Quarter 2026 Results on May 7, 2026

7:30 01-05-2026

JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical com...

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

7:30 09-04-2026

JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c...

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

7:30 31-03-2026

JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c...

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

7:30 30-03-2026

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical...

InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts

InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts

3:17 30-03-2026

InflaRx N.V. (NASDAQ: IFRX - Get Free Report) has been assigned a consensus recommendation of "Moder...

InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates

InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates

9:46 19-03-2026

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Est...

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

7:30 19-03-2026

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differe...

InflaRx to Report Full Year 2025 Results on March 19, 2026

InflaRx to Report Full Year 2025 Results on March 19, 2026

7:30 12-03-2026

JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical c...

InflaRx Announces Participation in February Investor Conferences

InflaRx Announces Participation in February Investor Conferences

7:30 29-01-2026

JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical co...

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts

5:24 11-01-2026

Shares of InflaRx N.V. (NASDAQ: IFRX - Get Free Report) have received a consensus rating of "Moderat...

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

8:00 08-01-2026

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase...

InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

7:08 05-01-2026

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare ...

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

7:30 30-12-2025

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlie...

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

7:30 11-12-2025

JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical co...

close

INFLARX ANNOUNCES PARTICIPATION IN FEBRUARY INVESTOR CONFERENCES

29-01-2026
JENA, GERMANY, JAN. 29, 2026 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX ANNOUNCES STRATEGY FOCUSED ON CAPITAL-EFFICIENT EXECUTION WITH IZICOPAN AND NEAR-TERM VALUE CREATION

08-01-2026
INFLARX TO PRIORITIZE IZICOPAN AS ITS LEADING PIPELINE ASSET, WITH A GOAL OF CONTINUING TOWARD PHASE...
Více zde

INFLARX PROVIDES UPDATE ON PHASE 3 DATA ANALYSES FOR VILOBELIMAB IN PYODERMA GANGRENOSUM

30-12-2025
WHILE THE PHASE 3 TRIAL OF VILOBELIMAB IN ULCERATIVE PYODERMA GANGRENOSUM (PG) WAS TERMINATED EARLIE...
Více zde

INFLARX ANNOUNCES INTERNATIONAL NONPROPRIETARY NAME OF “IZICOPAN” FOR INF904

11-12-2025
JENA, GERMANY, DEC. 11, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX REPORTS POSITIVE PHASE 2A DATA FOR INF904 IN HIDRADENITIS SUPPURATIVE (HS) AND CHRONIC SPONTANEOUS URTICARIA (CSU)

10-11-2025
PHASE 2A DATA SUPPORT ORAL C5AR INHIBITOR INF904 AS A POTENTIALLY TRANSFORMATIONAL AND BEST-IN-CLASS...
Více zde

INFLARX TO ANNOUNCE TOPLINE DATA FROM PHASE 2A CLINICAL TRIAL OF INF904 IN HIDRADENITIS SUPPURATIVA AND CHRONIC SPONTANEOUS URTICARIA

07-11-2025
COMPANY EXPECTS TO HOST A WEBCAST TO DISCUSS THE TOPLINE DATA ON MONDAY, NOVEMBER 10 AT 8:00 AM EST ...
Více zde

INFLARX ANNOUNCES PARTICIPATION IN THE GUGGENHEIM SECURITIES 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE

21-10-2025
JENA, GERMANY, OCT. 21, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

12-09-2025
JENA, GERMANY, SEPT. 12, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL C...
Více zde

INFLARX ANNOUNCES PARTICIPATION IN SEPTEMBER INVESTOR CONFERENCES

21-08-2025
JENA, GERMANY, AUG. 21, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-08-2025
JENA, GERMANY, AUG. 07, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX TO REPORT SECOND QUARTER 2025 RESULTS ON AUGUST 7, 2025

31-07-2025
JENA, GERMANY, JULY 31, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY NOTICE REGARDING MINIMUM BID PRICE REQUIREMENT

11-07-2025
JENA, GERMANY, JULY 11, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX ANNOUNCES OUTCOME OF INTERIM ANALYSIS FOR VILOBELIMAB PHASE 3 TRIAL IN PYODERMA GANGRENOSUM

28-05-2025
JENA, GERMANY, MAY 28, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL ...
Více zde

INFLARX TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

22-05-2025
JENA, GERMANY, MAY 22, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COM...
Více zde

INFLARX REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-05-2025
JENA, GERMANY, MAY 07, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COM...
Více zde

INFLARX TO REPORT FIRST QUARTER 2025 RESULTS ON MAY 7, 2025

30-04-2025
JENA, GERMANY, APRIL 30, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL C...
Více zde

INFLARX REPORTS FULL YEAR 2024 RESULTS AND HIGHLIGHTS KEY ACHIEVEMENTS AND EXPECTED MILESTONES

20-03-2025
JENA, GERMANY, MARCH 20, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL C...
Více zde

INFLARX SHOWCASES VILOBELIMAB'S ROLE IN IMMUNO-DERMATOLOGY AT THE 2025 AAD ANNUAL MEETING

07-03-2025
JENA, GERMANY, MARCH 07, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICA...
Více zde

INFLARX TO SHOWCASE VILOBELIMAB'S ROLE IN IMMUNO-DERMATOLOGY AT THE 2025 AAD ANNUAL MEETING

28-02-2025
JENA, GERMANY, FEB. 28, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL...
Více zde

INFLARX TO REPORT FULL YEAR 2024 RESULTS ON MARCH 20 AND ANNOUNCES PARTICIPATION IN MARCH INVESTOR CONFERENCES

25-02-2025
JENA, GERMANY, FEB. 25, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX ANNOUNCES CLOSING OF $30 MILLION PUBLIC OFFERING OF ORDINARY SHARES AND PRE-FUNDED WARRANTS

18-02-2025
JENA, GERMANY, FEB. 18, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX) (THE “COMPANY”), A ...
Více zde

INFLARX ANNOUNCES PRICING OF $30 MILLION PUBLIC OFFERING OF ORDINARY SHARES AND PRE-FUNDED WARRANTS

13-02-2025
JENA, GERMANY, FEB. 13, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX) (THE “COMPANY”), A ...
Více zde

INFLARX ANNOUNCES PUBLIC OFFERING OF ORDINARY SHARES AND PRE-FUNDED WARRANTS

13-02-2025
JENA, GERMANY, FEB. 13, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX) (THE “COMPANY”), A ...
Více zde

INFLARX ANNOUNCES PARTICIPATION IN GUGGENHEIM SMID CAP BIOTECH CONFERENCE

23-01-2025
JENA, GERMANY, JAN. 23, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL CO...
Více zde

INFLARX RECEIVES EUROPEAN COMMISSION APPROVAL FOR GOHIBIC® (VILOBELIMAB) FOR THE TREATMENT OF SARS-COV-2-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

15-01-2025
JENA, GERMANY, JAN. 15, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL...
Více zde

INFLARX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A STUDY FOR ORAL C5AR INHIBITOR INF904

20-12-2024
JENA, GERMANY, DEC. 20, 2024 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICA...
Více zde

INFLARX RECEIVES POSITIVE CHMP OPINION FOR GOHIBIC® (VILOBELIMAB) FOR THE TREATMENT OF SARS-COV-2-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME

15-11-2024
JENA, GERMANY, NOV. 15, 2024 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL...
Více zde

INFLARX REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

08-11-2024
JENA, GERMANY, NOV. 08, 2024 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL...
Více zde

INFLARX PRESENTS POST HOC ANALYSIS OF SHINE TRIAL OF VILOBELIMAB IN HIDRADENITIS SUPPURATIVA AT THE 2024 EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY CONGRESS

25-09-2024
JENA, GERMANY, SEPT. 25, 2024 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICA...
Více zde

INFLARX PRESENTS NEW PRECLINICAL FINDINGS FOR INF904 AT THE 19TH EUROPEAN MEETING ON COMPLEMENT IN HUMAN DISEASES

03-09-2024
JENA, GERMANY, SEPT. 03, 2024 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICA...
Více zde

close

Dokumenty nejsou k dispozici

preloader